Kevin O’Leary says now is the buying opportunity of a lifetime in Europe.
As the world tries to make sense of the U.K.'s historic vote, three sectors could be especially hard hit.
Companies and people are issuing statements about the United Kingdom's decision to leave the European Union. We've got the latest list.
Inovio's Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin.
Some common weight-loss drugs seem to work better than others, according to a new study in a respected medical journal.
Some of the names on the move ahead of the open.
European stocks closed sharply lower on Monday amid a global selloff, as uncertainty over a possible "Brexit" and looming central bank meetings shook markets.
Bookmakers, sportswear and travel seem a safe bet to profit from a large sporting event, but are they the best stocks to hold?
CNBC's Meg Tirrell reports on a new gene therapy to help blind people.
A gene therapy from Spark Therapeutics is offering patients with a rare genetic retinal disease that causes blindness some hope.
Scientists are working on a new treatment for depression and PTSD: deep-brain stimulation.
When we think about taking medicines, we imagine popping a pill, or receiving a shot. But a new approach would leverage the body's electrical signals.
European markets finished mostly mixed on Thursday, as investors digested the latest slew of earnings amid a rise in oil prices.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Andrew Witty, GlaxoSmithKline CEO, discusses drug pricing in the United States, innovations in health care, & more.
Increasing sales of new products and growing demand for vaccines and consumer healthcare goods helped lift GlaxoSmithKline's sales figures 8 percent.
GSK CEO, Sir Andrew Witty says he’s delighted with the progress and the vast majority of the new products that GSK has delivered in terms of sales.
Will GSK cave in to critics’ pressure and sell off chunks of its business? Its CEO, Sir Andrew Witty, weighs in.
GSK CEO Sir Andrew Witty explains why he still believes the U.K. is better off in the EU.
GSK CEO Sir Andrew Witty outlines the key factors to take away from the company’s latest earnings, saying it’s on-track to get a margin above 30 percent.